Colchicine demonstrates a high level of efficacy in reducing complications from COVID-19 in outpatients.
According to the conclusions of the study of the Montreal Heart Institute, recently published, colchicine slows the pulmonary inflammatory process, the need for hospitalization and also the number of deaths from COVID-19. The COLCORONA clinical study, carried out with more than 4,000 patients in Canada, the US, Europe, South Africa and some countries in South America, has shown that colchicine is capable of reducing the risk of death from COVID-19 by 44%, as well such as hospitalizations, by 25%, and the need for mechanical ventilation, by 50%.
Dr. Jean-Claude Tardif, Director of the MHI Research Center and Principal Investigator of the COLCORONA trial, assures that: “Research has demonstrated the efficacy of colchicine treatment to prevent cytokine storm phenomenon and reduce complications associated with COVID-19 “.
The data from the COLCORONA study open the possibility that the product (which in Spain is marketed under the Colchicina Seid brand, as a treatment for gout) could be used on an outpatient basis, under medical prescription, to avoid symptomatic progression in patients diagnosed with COVID .
To date, COLCORONA is the largest study conducted with an orally administered drug in non-hospitalized patients with COVID-19.
For more information about COLCHICINA SEID, see the following link: